
    
      To evaluate the safety and efficacy of Luminate® (ALG-1001) as compared to Avastin® in
      patients with diabetic macular edema

      - Stage 1: 120 eligible subjects with DME will be enrolled and randomized to one of 4
      treatment groups at an allocation ratio of 1:1:1:1, i.e., one of three doses (1.0 mg, 2.0 mg
      and 3.0 mg) of Luminate intravitreal injection or Avastin intravitreal injection. Subjects
      will be followed monthly for 24 weeks (6 months).

      Stage 2 (select sites): 75 eligible subjects with DME will be enrolled and randomized to one
      of 5 treatment groups at an allocation ratio of 1:1:1:1:1; i.e., one of 2 doses of Luminate
      intravitreal injection or Avastin intravitreal injection (0.5 mg and 1.0 mg). Subjects will
      be followed monthly for 20 weeks (5 months).
    
  